Stock Research: MedinCell

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

MedinCell

ENXTPA:MEDCL FR0004065605
22
  • Value
    20
  • Growth
    100
  • Safety
    Safety
    4
  • Combined
    26
  • Sentiment
    22
  • 360° View
    360° View
    22
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Medincell SA is a France-based manufacturer of biological products and pharmaceutical preparations. The company develops therapeutic solutions with worldwide access, collaborating with pharmaceutical corporations, physicians, biotechnology firms, academics, and foundations. Their main businesses include developing long-acting injectable medicines for various therapeutic areas such as schizophrenia, post-surgical pain and inflammation, contraception, and depression. In the last fiscal year, the company had a market cap of $622 million and revenue of $27 million.

more
Index
CAC All
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 18-Dec-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
20 22 41 56
Growth
100 92 87 5
Safety
Safety
4 4 1 8
Sentiment
22 27 20 20
360° View
360° View
22 23 8 4
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
95 87 93 87
Opinions Change
11 28 17 50
Pro Holdings
n/a 38 47 8
Market Pulse
21 1 3 11
Sentiment
22 27 20 20
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
20 22 41 56
Growth
100 92 87 5
Safety Safety
4 4 1 8
Combined
26 26 26 4
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
3 1 100 68
Price vs. Earnings (P/E)
5 5 16 34
Price vs. Book (P/B)
100 100 100 100
Dividend Yield
1 1 1 1
Value
20 22 41 56
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
98 98 100 28
Profit Growth
73 51 67 28
Capital Growth
96 83 31 16
Stock Returns
81 88 60 14
Growth
100 92 87 5
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
1 1 1 3
Refinancing
17 21 1 52
Liquidity
19 19 19 17
Safety Safety
4 4 1 8

Similar Stocks

Discover high‑ranked alternatives to MedinCell and broaden your portfolio horizons.

Synergie

ENXTPA:SDG
Country: France
Industry: HR- & Employment Services
Size: Medium
Full Stock Analysis

Rubis

ENXTPA:RUI
Country: France
Industry: Gas Utilities
Size: Medium
Full Stock Analysis

Krka

LJSE:KRKG
Country: Slovenia
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

ENGIE

ENXTPA:ENGI
Country: France
Industry: Multi-Utilities
Size: Large
Full Stock Analysis

Frequently Asked
Questions

The only positive is high growth. The stock is expensive (low Value Rank), risky to finance, and carries critical professional sentiment. This is a risky proposition. Avoid unless you have exceptional conviction that the growth alone will overcome the price and financial risks.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: